Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
23. Dezember 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets...
浩鼎、日本頂尖醣化學衍生技術公司 GlyTech簽署二協議
23. Dezember 2024 04:00 ET
|
OBI Pharma Inc.
台灣台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎(4174.TWO)23日發布，與日本專注於聚醣生產和醣化學衍生技術的GlyTech, Inc.，簽署行銷和材料移轉兩項協議；日後將藉GlyTech之力，推廣日本生技製藥業採用浩鼎自主開發的GlycOBI® ADC (antibody-drug conjugate) 關鍵技術，以創造雙贏，雙方共享利益。 ...
浩鼎、日本顶尖糖化学衍生技术公司 GlyTech 签署二协议
23. Dezember 2024 04:00 ET
|
OBI Pharma Inc.
台湾台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎(4174.TWO)23日发布，与日本专注于聚糖生产和糖化学衍生技术的GlyTech, Inc.，签署行销和材料移转两项协议；日后将借GlyTech之力，推广日本生技制药业采用浩鼎自主开发的GlycOBI® ADC (antibody-drug conjugate) 关键技术，以创造双赢，双方共享利益。 ...
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
23. Dezember 2024 04:00 ET
|
OBI Pharma Inc.
OBI Pharma collaborates with GlyTech to advance GlycOBI® technologies in Japan, enhancing glycan production and enabling novel ADC therapeutic innovations.
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
19. Dezember 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Marker Therapeutics Announces $16.1 Million Private Placement
19. Dezember 2024 08:06 ET
|
Marker Therapeutics
HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
19. Dezember 2024 08:05 ET
|
Marker Therapeutics
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well...
Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
19. Dezember 2024 08:00 ET
|
Artios Pharma
CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...
Immuneering Launches Pancreatic Cancer Advisory Board
19. Dezember 2024 08:00 ET
|
Immuneering Corporation
Immuneering Launches Pancreatic Cancer Advisory Board
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
18. Dezember 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by...